Trevena has carved out a niche in seeking so-called 'biased ligands'--GPCR-binding compounds that selectively activate just one (or a few) of the many biological pathways mediated via a particular GPCR complex. By identifying a ligand that hits the pathways responsible for a medicine's benefits, and avoiding those behind the ill effects, the company hopes to develop safer and more effective therapies, initially in CNS and cardiovascular disease.

In Vivo briefly describes these recently founded companies: AgileNano, Applied Catheter Technologies, Coromedic, EpiTherapeutics, GPC-Rx and RCP Therapeutics.

Brief profiles of these recently formed companies: Coromedic, GPC-Rx, RCP Therapeutics, Reflectance Medical.